As the pharmaceutical industry continues to advance, there is an increasing number of identified drug targets and new modalities that require novel small molecule space.
MyxoTech offers a library of novel chemistry produced by a group of bacteria that exist on the fringe of microbial dark matter. This pool of small molecules contains proven bioactives that act on diverse targets. Corallopyronin A, projected for phase I clinical trials in 2026 for treatment of filarial infection, and breast cancer drug Ixabepilone's precursor epothilone B exemplify the value of the library.
We additionally provide a menu of downstream services, including drug lead and production titer optimization.
MyxoTech is an outsourced preclinical natural product pipeline adaptable for you drug development needs.
Company Details
- Employees
- 3
- Address
- Campus E8.1, Saarbruecken,66123,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://myxotech.com
- Keywords
- IT Consulting.
- HQ
- Saarbruecken
Myxotech Questions
Myxotech's website is http://myxotech.com
Myxotech's LinkedIn profile is https://de.linkedin.com/company/myxotech
Myxotech has
3 employees.
View email and phone details for 3
employees at Myxotech.
Myxotech's industry is
Biotechnology Research
Myxotech's top competitors are
Lifetaq-Analytics Gmbh,
Gsk,
Unicorn Biotechnologies,
Argent Associates, Inc.,
Center For Bioinformatics - Saarland University,
Socal Biosciences, Inc.,
Cleanlight,
Nestegg Labs,
Ja Chessmen,
Phabioc.
Myxotech's categories are Biotechnology Research
